Celcuity Inc (CELC)

$8.04 -0.81 (-9.15%)
Market Cap 344.94M
Revenue (ttm) 0.00
Net Income (ttm) -63.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.65
Volume 275,997
Avg Vol 268,338
Day's Range N/A - N/A
Shares Out 37.13M
Stochastic %K 13%
Beta 0.44
Analysts Strong Sell
Price Target $30.43

Latest News on CELC

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Apr 1, 2025, 7:05 AM EDT - 3 days ago

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 10:50 PM EDT - 3 days ago

Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 4:01 PM EDT - 3 days ago

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Mar 24, 2025, 7:05 AM EDT - 11 days ago

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

Feb 25, 2025, 7:05 AM EST - 5 weeks ago

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

Celcuity's High-Stakes Oncology Bet Is Underappreciated

Feb 19, 2025, 6:24 PM EST - 6 weeks ago

Celcuity's High-Stakes Oncology Bet Is Underappreciated

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Dec 11, 2024, 7:05 AM EST - 4 months ago

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:42 PM EST - 5 months ago

Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

Nov 14, 2024, 4:01 PM EST - 5 months ago

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

Nov 12, 2024, 7:05 AM EST - 5 months ago

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

Nov 7, 2024, 7:05 AM EST - 5 months ago

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript

Aug 16, 2024, 3:50 PM EDT - 8 months ago

Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

Aug 14, 2024, 4:01 PM EDT - 8 months ago

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

Aug 7, 2024, 7:05 AM EDT - 8 months ago

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

Celcuity: Flying A Phase 3 Trial Right Under Your Nose

Jul 5, 2024, 12:05 AM EDT - 9 months ago

Celcuity: Flying A Phase 3 Trial Right Under Your Nose

Celcuity To Participate in Jefferies Global Healthcare Conference

Jun 3, 2024, 4:01 PM EDT - 10 months ago

Celcuity To Participate in Jefferies Global Healthcare Conference

Celcuity Announces Pricing of Underwritten Common Stock Offering

May 30, 2024, 7:36 AM EDT - 11 months ago

Celcuity Announces Pricing of Underwritten Common Stock Offering

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

May 30, 2024, 7:00 AM EDT - 11 months ago

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript

May 15, 2024, 7:43 PM EDT - 11 months ago

Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript

Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update

May 15, 2024, 4:01 PM EDT - 11 months ago

Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

May 8, 2024, 7:05 AM EDT - 11 months ago

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 6:40 PM EDT - 1 year ago

Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

Mar 20, 2024, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

Mar 6, 2024, 7:05 AM EST - 1 year ago

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

Celcuity to Participate in Cowen's 44th Annual Health Care Conference

Feb 28, 2024, 7:05 AM EST - 1 year ago

Celcuity to Participate in Cowen's 44th Annual Health Care Conference

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

Feb 20, 2024, 7:05 AM EST - 1 year ago

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

Dec 6, 2023, 8:30 AM EST - 1 year ago

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

Dec 1, 2023, 11:02 AM EST - 1 year ago

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 22, 2023, 8:05 AM EST - 1 year ago

Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Celcuity Inc. (CELC) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 12:41 PM EST - 1 year ago

Celcuity Inc. (CELC) Q3 2023 Earnings Call Transcript

Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Nov 13, 2023, 7:05 AM EST - 1 year ago

Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call

Nov 6, 2023, 7:30 AM EST - 1 year ago

Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call

Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences

Nov 1, 2023, 7:05 AM EDT - 1 year ago

Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences

Celcuity Inc. Announces $50 Million Private Placement

Oct 18, 2023, 9:15 AM EDT - 1 year ago

Celcuity Inc. Announces $50 Million Private Placement

Celcuity to Host Virtual Science Day for Investors

Sep 7, 2023, 4:05 PM EDT - 1 year ago

Celcuity to Host Virtual Science Day for Investors

Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial

Aug 22, 2023, 4:05 PM EDT - 1 year ago

Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial

Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

Aug 22, 2023, 4:01 PM EDT - 1 year ago

Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

Celcuity Inc. (CELC) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 8:15 PM EDT - 1 year ago

Celcuity Inc. (CELC) Q2 2023 Earnings Call Transcript

Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Aug 10, 2023, 4:04 PM EDT - 1 year ago

Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call

Aug 3, 2023, 7:30 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call

Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023

Jul 31, 2023, 8:00 AM EDT - 1 year ago

Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023

Celcuity Set to Join Russell 2000 and 3000 Indexes

Jun 20, 2023, 9:02 AM EDT - 1 year ago

Celcuity Set to Join Russell 2000 and 3000 Indexes

Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

May 24, 2023, 8:00 AM EDT - 2 years ago

Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

Celcuity Inc. (CELC) Q1 2023 Earnings Call Transcript

May 15, 2023, 10:47 PM EDT - 2 years ago

Celcuity Inc. (CELC) Q1 2023 Earnings Call Transcript

Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates

May 15, 2023, 4:00 PM EDT - 2 years ago

Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress

May 12, 2023, 6:15 AM EDT - 2 years ago

Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress

Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call

May 8, 2023, 5:30 PM EDT - 2 years ago

Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call

Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress

May 8, 2023, 8:00 AM EDT - 2 years ago

Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

Apr 18, 2023, 1:30 PM EDT - 2 years ago

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023